Diagnosis and Treatment of Intracardiac Thrombus.
Journal
Journal of cardiovascular pharmacology
ISSN: 1533-4023
Titre abrégé: J Cardiovasc Pharmacol
Pays: United States
ID NLM: 7902492
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
received:
15
02
2021
accepted:
01
05
2021
pubmed:
3
6
2021
medline:
10
2
2022
entrez:
2
6
2021
Statut:
ppublish
Résumé
Intracardiac thrombi can occur in a variety of locations and are frequently encountered in clinical practice. Yet evidence-based guidance for clinicians managing patients with intracardiac thrombi is often limited. This review summarizes what is known regarding the prevalence of intracardiac thrombus, diagnostic strategies, clinical relevance, and treatment options, focusing on four specific types of thrombus for which recent research has shifted clinical understanding and treatment decisions: (1) left atrial appendage thrombus, (2) cardiac implantable electronic device lead thrombus, (3) bioprosthetic aortic valve thrombus, and (4) left ventricular thrombus. Additional studies, ideally prospective, randomized, and head-to-head in design, are needed to better inform best practices in patients with intracardiac thrombi.
Identifiants
pubmed: 34074905
doi: 10.1097/FJC.0000000000001064
pii: 00005344-202109000-00005
doi:
Substances chimiques
Anticoagulants
0
Fibrinolytic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-371Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Koupenova M, Kehrel BE, Corkrey HA, et al. Thrombosis and platelets: an update. Eur Heart J. 2017;38:785–791.
Chernysh IN, Nagaswami C, Kosolapova S, et al. The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli. Sci Rep. 2020;10:5112.
Stokes K, Chem B, Anderson J, et al. The encapsulation of polyurethane-insulated tranvenous cardiac pacemaker leads. Cardiovasc Pathol. 1995;4:163–171.
Dangas GD, Weitz JI, Giustino G, et al. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 2016;68:2670–2689.
Zhan Y, Joza J, Al Rawahi M, et al. Assessment and management of the left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2018;34:252–261.
Wyrembak J, Campbell KB, Steinberg BA, et al. Incidence and predictors of left atrial appendage thrombus in patients treated with nonvitamin K oral anticoagulants versus warfarin before catheter ablation for atrial fibrillation. Am J Cardiol. 2017;119:1017–1022.
Niku AD, Shiota T, Siegel RJ, et al. Prevalence and resolution of left atrial thrombus in patients with nonvalvular atrial fibrillation and flutter with oral anticoagulation. Am J Cardiol. 2019;123:63–68.
Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation. 2014;129:2094–2099.
Sajeev JK, Kalman JM, Dewey H, et al. The atrium and embolic stroke: myopathy not atrial fibrillation as the requisite determinant? JACC Clin Electrophysiol. 2020;6:251–261.
Packer M HFpEF is the substrate for stroke in obesity and diabetes independent of atrial fibrillation. JACC Hear Fail. 2020;8:35–42.
Collins LJ, Silverman DI, Douglas PS, et al. Cardioversion of nonrheumatic atrial fibrillation. Circulation. 1995;92:160–163.
Vira T, Pechlivanoglou P, Connelly K, et al. Cardiac computed tomography and magnetic resonance imaging vs. transoesophageal echocardiography for diagnosing left atrial appendage thrombi. Europace. 2019;21:E1–E10.
Frost L, Engholm G, Johnsen S, et al. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med. 2001;161:272–276.
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the framingham study. Stroke 1991;22:983–988.
Jaber WA, Prior DL, Thamilarasan M, et al. Efficacy of anticoagulation in resolving left atrial and left atrial appendage thrombi: a transesophageal echocardiographic study. Am Heart J. 2000;140:150–156.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart R. J Am Coll Cardiol. 2019;74:104–132.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–867.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
Corrado G, Tadeo G, Beretta S, et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Chest. 1999;115:140–143.
Lip GYH, Hammerstingl C, Marin F, et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126–134.
Lin C, Quan J, Bao Y, et al. Outcome of non‐vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. J Cardiovasc Electrophysiol. 2020;31:658–663.
Fleddermann A, Eckert R, Muskala P, et al. Efficacy of direct acting oral anticoagulant drugs in treatment of left atrial appendage thrombus in patients with atrial fibrillation. Am J Cardiol. 2019;123:57–62.
Ezekowitz MD, Pollack CV, Halperin JL, et al. Apixaban compared to heparin/Vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. Eur Heart J. 2018;39:2959–2971.
Piotrowski R, Zaborska B, Pilichowska-paszkiet E, et al. RIVAroxaban TWICE daily for lysis of thrombus in the left atrial appendage in patients with non-valvular atrial fibrillation: the RIVA-TWICE study. Arch Med Sci. 2020;16:289–296.
Masson P, Kelly PJ, Craig JC, et al. Risk of stroke in patients with ESRD. Clin J Am Soc Nephrol. 2015;10:1585–1592.
Molnar AO, Bota SE, Garg AX, et al. The risk of major hemorrhage with CKD. J Am Soc Nephrol. 2016;27:2825–2832.
Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation. 2018;138:1519–1529.
Kuno T, Takagi H, Ando T, et al. Oral anticoagulation for patients with atrial fibrillation on long-term hemodialysis. J Am Coll Cardiol. 2020;75:273–285.
Dukkipati SR, Kar S, Holmes DR, et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138:874–885.
Novak M, Dvorak P, Kamaryt P, et al. Autopsy and clinical context in deceased patients with implanted pacemakers and defibrillators: intracardiac findings near their leads and electrodes. Europace. 2009;11:1510–1516.
Supple GE, Ren JF, Zado ES, et al. Mobile thrombus on device leads in patients undergoing ablation: identification, incidence, location, and association with increased pulmonary artery systolic pressure. Circulation. 2011;124:772–778.
Korkeila PJ, Saraste MK, Nyman KM, et al. Transesophageal echocardiography in the diagnosis of thrombosis associated with permanent transvenous pacemaker electrodes. Pacing Clin Electrophysiol. 2006;29:1245–1250.
Rahbar AS, Azadani PN, Thatipelli S, et al. Risk factors and prognosis for clot formation on cardiac device leads. Pacing Clin Electrophysiol. 2013;36:1294–1300.
Noheria A, Ponamgi SP, DeSimone CV, et al. Pulmonary embolism in patients with transvenous cardiac implantable electronic device leads. Europace. 2016;18:246–252.
Mojadidi MK, Zaman MO, Elgendy IY, et al. Cryptogenic stroke and patent foramen ovale. J Am Coll Cardiol. 2018;71:1035–1043.
Desimone CV, Friedman PA, Noheria A, et al. Stroke or transient ischemic attack in patients with transvenous pacemaker or defibrillator and echocardiographically detected patent foramen ovale. Circulation. 2013;128:1433–1441.
Sugrue A, DeSimone CV, Lenz CJ, et al. Mobile thrombus on cardiac implantable electronic device leads of patients undergoing cardiac ablation: incidence, management, and outcomes. J Interv Card Electrophysiol. 2016;46:115–120.
Randall MH, Bavry AA. Update on transcatheter aortic valve replacement. Cardiol Ther. 2020;9:75–84.
Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017;389:2383–2392.
Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. J Am Coll Cardiol. 2020;75:3003–3015.
Hansson NC, Grove EL, Andersen HR, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68:2059–2069.
Pache G, Schoechlin S, Blanke P, et al. Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. 2016;37:2263–2271.
Yanagisawa R, Hayashida K, Yamada Y, et al. Incidence, predictors, and mid-term outcomes of possible leaflet thrombosis after TAVR. JACC Cardiovasc Imaging. 2017;10:1–11.
Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2015;373:2015–2024.
Ruile P, Jander N, Blanke P, et al. Course of early subclinical leaflet thrombosis after transcatheter aortic valve implantation with or without oral anticoagulation. Clin Res Cardiol. 2017;106:85–95.
Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound. A report from the American society of echocardiography's guidelines and standards committee and the task force on prosthetic valves, developed in conjunction. J Am Soc Echocardiogr. 2009;22:975–1014.
Nishimura RA, Otto CM. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2017;135:e1159–e1195.
Brennan JM, Edwards FH, Zhao Y, et al. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database. J Am Coll Cardiol. 2012;60:971–977.
Mérie C, Køber L, Skov Olsen P, et al. Association of warfarin therapy duration with risk of mortality , thromboembolic. J Am Med Assoc. 2012;308:2118–2125.
Chakravarty T, Patel A, Kapadia S, et al. Anticoagulation after surgical or transcatheter bioprosthetic aortic valve replacement. J Am Coll Cardiol. 2019;74:1190–1200.
Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120–129.
Habash F, Vallurapalli S. Challenges in management of left ventricular thrombus. Ther Adv Cardiovasc Dis. 2017;11:203–213.
Robinson AA, Jain A, Gentry M, et al. Left ventricular thrombi after STEMI in the primary PCI era: a systematic review and meta-analysis. Int J Cardiol. 2016;221:554–559.
Lee JM, Park JJ, Jung HW, et al. Left ventricular thrombus and subsequent thromboembolism, comparison of anticoagulation, surgical removal, and antiplatelet agents. J Atheroscler Thromb. 2013;20:73–93.
Lattuca B, Bouziri N, Kerneis M, et al. Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol. 2020;75:1676–1685.
McCarthy CP, Murphy S, Venkateswaran RV, et al. Left ventricular thrombus: contemporary etiologies, treatment strategies, and outcomes. J Am Coll Cardiol. 2019;73:2007–2009.
Lee GY, Song YBin, Hahn JY, et al. Anticoagulation in ischemic left ventricular aneurysm. Mayo Clin Proc. 2015;90:441–449.
Heckle MR, McCoy CW, Akinseye OA, et al. Stress-induced thrombus: prevalence of thromboembolic events and the role of anticoagulation in Takotsubo cardiomyopathy. Ann Transl Med. 2018;6:4.
Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386:813–825.
Visser CA, Kan G, David GK, et al. Two dimensional echocardiography in the diagnosis of left ventricular thrombus. A prospective study of 67 patients with anatomic validation. Chest. 1983;83:228–232.
Roifman I, Connelly KA, Wright GA, et al. Echocardiography vs cardiac magnetic resonance imagingfor the diagnosis of left ventricular thrombus: a systematic review. Can J Cardiol. 2015;31:785–791.
Velangi PS, Choo C, Chen KHA, et al. Long-term embolic outcomes after detection of left ventricular thrombus by late gadolinium enhancement cardiovascular magnetic resonance imaging: a matched cohort study. Circ Cardiovasc Imaging. 2019;12:e009723.
Bittencourt MS, Achenbach S, Marwan M, et al. Left ventricular thrombus attenuation characterization in cardiac computed tomography angiography. J Cardiovasc Comput Tomogr. 2012;6:121–126.
Srichai MB, Junor C, Rodriguez LL, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J. 2006;152:75–84.
Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol. 1993;22:1004–1009.
Johannessen KA, Nordrehaug JE, Von der Lippe G, et al. Risk factors for embolisation in patients with left ventricular thrombi and acute myocardial infarction. Br Heart J. 1988;60:104–110.
Robinson AA, Trankle CR, Eubanks G, et al. Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020;5:685–692.
Homma S, Thompson JLP, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med. 2012;355:1859–1869.
Homma S, Thompson JLP, Qian M, et al. Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: warfarin versus aspirin in reduced cardiac ejection fraction trial substudy. Circ Hear Fail. 2015;8:504–509.
Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332–1342.
Meurin P, Tabet JY, Renaud N, et al. Treatment of left ventricular thrombi with a low molecular weight heparin. Int J Cardiol. 2005;98:319–323.
Smetana KS, Dunne J, Parrott K, et al. Oral factor Xa inhibitors for the treatment of left ventricular thrombus: a case series. J Thromb Thrombolysis. 2017;44:519–524.
Fleddermann AM, Hayes CH, Magalski A, et al. Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus. Am J Cardiol. 2019;124:367–372.
Abdelnabi M, Saleh Y, Fareed A, et al. Comparative study of oral anticoagulation in left ventricular thrombi (No-lvt trial) (abstr). Available at: https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=14edff5e70174cc49959724ab9b68efc . Published 2020. Accessed November 27, 2020.